Table 5.
In vivo anticancer effects of Lebanese D. carota ssp. carota.
| Cancer Model | Extracts/Compounds | Mode of Treatment (Dose and Frequency of Administration) |
Results | References |
|---|---|---|---|---|
| DMBA/TPA-induced skin carcinogenesis model in mice | Methanol/Acetone (1:1) Daucus carota oil extract (DCOE) | Gavage, 20 μL of 100% oil Intraperitoneal, 0.3 mL of 2% oil. Topical, 0.2 mL of 100% oil; 50% oil; 5% oil. |
Minimal effects seen with gavage administration. Significant decrease in tumor volume, delay in tumor appearance, and inhibition of tumor incidence and yield with intraperitoneal and topical administration. |
[65] |
| Chemoprevention: Pre-treatment with DCOE (25 mg/kg) a week prior to cancer induction Treatment twice weekly for 14 weeks. Chemotherapeutic: DCOE (25 mg/kg body weight; IP; thrice a week for 8 weeks). |
Reduced tumor incidence. Protection against DMBA-induced toxicity. Significant inhibition of tumor volume. No decrease in body weight as compared to cisplatin. |
[80] | ||
| Pentane: diethyl ether (50:50) fraction (F2) | Intraperitoneal treatment (10–200 mg/kg) | Significant inhibition of papilloma incidence, yield, and volume at weeks 15, 18, and 21. | [91] | |
| β-2-himachalen-6-ol (HC) | Topical (5%). Intraperitoneal HC (25 mg/kg). |
Significant decrease in papilloma yield and volume at weeks 12, 16, and 18, and increase in survival rates. No decrease in weight with HC (safer). |
[93] | |
| Topical (5%). Intraperitoneal HC (10, 25, and 50 mg/kg). |
Significant decrease in papilloma yield, incidence, and volume, and twofold to threefold increase in survival rates. |
[95] |